Published in Blood on August 02, 2012
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens (2013) 1.22
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood (2014) 1.20
Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nat Commun (2014) 1.01
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. Blood (2013) 0.91
Proceedings: human leukocyte antigen haplo-homozygous induced pluripotent stem cell haplobank modeled after the california population: evaluating matching in a multiethnic and admixed population. Stem Cells Transl Med (2015) 0.87
The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation. EMBO Mol Med (2015) 0.86
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. Blood (2016) 0.84
In silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem-Cell Transplant Donors and Recipients: Understanding the Quantitative Immunobiology of Allogeneic Transplantation. Front Immunol (2014) 0.83
Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients. Front Immunol (2014) 0.82
Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol (2016) 0.82
Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica (2015) 0.81
Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. Leukemia (2016) 0.78
LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application. Haematologica (2015) 0.78
HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response-Implications on HSCT Outcome. Stem Cells Int (2015) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. PLoS One (2016) 0.76
Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease. Chimerism (2015) 0.75
Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation. Eur J Hum Genet (2013) 0.75
Modulation of antigen processing by haem-oxygenase 1. Implications on inflammation and tolerance. Immunology (2016) 0.75
Haplotyping the human leukocyte antigen system from single chromosomes. Sci Rep (2016) 0.75
PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells. J Immunol Res (2016) 0.75
Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget (2017) 0.75
The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants. PLoS One (2016) 0.75
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood (2016) 0.75
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
A haplotype map of the human genome. Nature (2005) 105.70
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet (2006) 15.63
Structure of the human class I histocompatibility antigen, HLA-A2. Nature (1987) 14.54
The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature (2003) 12.44
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (1993) 8.75
Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science (1998) 5.05
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics (2008) 4.25
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2008) 3.18
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Y-antigen killing by T cells of women is restricted by HLA. Nature (1977) 2.73
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol (2012) 2.68
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63
Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet (2008) 2.58
Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science (1995) 2.55
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol (2001) 2.43
Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med (2000) 2.30
Detection of structural variants and indels within exome data. Nat Methods (2011) 2.27
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science (1998) 2.11
Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells. J Exp Med (1991) 2.09
Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet (2003) 2.08
Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro. Blood (2010) 1.99
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood (2007) 1.96
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood (2009) 1.86
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med (2004) 1.84
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood (2003) 1.79
National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant (2008) 1.78
HapMap scanning of novel human minor histocompatibility antigens. Blood (2008) 1.75
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood (2009) 1.74
A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med (2003) 1.72
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med (2003) 1.61
A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med (1999) 1.60
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol (2000) 1.49
HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood (2008) 1.44
The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood (2002) 1.41
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood (2003) 1.40
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet (2009) 1.40
Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol (1999) 1.38
Minor histocompatibility antigen HA-1 and HPA-5 polymorphisms in HLA-identical related bone marrow transplantation. Transplant Proc (2004) 1.37
Deep sequencing of the human TCRγ and TCRβ repertoires suggests that TCRβ rearranges after αβ and γδ T cell commitment. Sci Transl Med (2011) 1.36
A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest (2005) 1.33
Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol (1995) 1.31
Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood (2010) 1.30
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J (2001) 1.28
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood (2007) 1.23
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 1.21
Alloimmunity to human H-Y. Lancet (1976) 1.20
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant (2008) 1.20
Impact of highly conserved HLA haplotype on acute graft-versus-host disease. Blood (2010) 1.19
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J Immunol (2002) 1.16
Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.14
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med (2008) 1.14
High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res (2010) 1.14
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol (2011) 1.14
Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 1.11
Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival. J Clin Invest (1977) 1.10
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant (2009) 1.09
Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.07
Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells. J Clin Invest (1988) 1.05
The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol (2005) 1.05
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci (2011) 1.02
Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant (1991) 1.01
Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev (2011) 0.99
Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Haematologica (2012) 0.95
Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol (2002) 0.95
Adrenal homografts in mice, with special reference to immunological adrenalectomy. Immunology (1958) 0.94
HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia (2008) 0.94
Peripheral blood stem cell allograft rejection mediated by CD4(+) T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901. Blood (2001) 0.92
A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol (2004) 0.91
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation (2007) 0.91
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation (2011) 0.91
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res (2010) 0.91
Immune privilege in the testis. I. Basic parameters of allograft survival. Transplantation (1983) 0.89
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc Natl Acad Sci U S A (2009) 0.89
Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch. J Clin Invest (1996) 0.89
Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities. Blood (2010) 0.87
Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia (2010) 0.87
Exploration of the genetic basis of GVHD by genetic association studies. Biol Blood Marrow Transplant (2009) 0.87
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis (2011) 9.37
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
A fine-scale linkage-disequilibrium measure based on length of haplotype sharing. Am J Hum Genet (2006) 6.02
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.15
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med (2003) 3.30
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol (2008) 2.99
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis (2011) 2.89
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood (2004) 2.77
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA (2004) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep (2004) 2.53
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol (2005) 2.41
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst (2003) 2.29
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood (2004) 2.28
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
Gene expression analyzed by high-resolution state array analysis and quantitative proteomics: response of yeast to mating pheromone. Mol Cell Proteomics (2004) 2.22
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol (2005) 2.11
Evidence for early right ventricular and septal mechanical activation (interventricular dyssynchrony) in pulmonary hypertension. Am J Cardiol (2008) 2.08
Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol (2005) 2.04
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood (2012) 2.00
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood (2006) 1.95
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 1.94
Estimating haplotype frequencies and standard errors for multiple single nucleotide polymorphisms. Biostatistics (2003) 1.91
A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med (2006) 1.91
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA (2009) 1.88
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood (2002) 1.80
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant (2008) 1.75
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood (2003) 1.72
Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One (2013) 1.71
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol (2011) 1.70
Low birth weight and respiratory disease in adulthood: a population-based case-control study. Am J Respir Crit Care Med (2009) 1.68
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest (2014) 1.66
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 1.65
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol (2006) 1.63
Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology. J Ethnopharmacol (2012) 1.63
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol (2006) 1.62
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant (2013) 1.62
Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2008) 1.60
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood (2003) 1.59
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood (2008) 1.59